229 related articles for article (PubMed ID: 22591669)
1. Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention.
Bertrand OF; Jolly SS; Rao SV; Patel T; Belle L; Bernat I; Parodi G; Costerousse O; Mann T
Am J Cardiol; 2012 Aug; 110(4):599-606. PubMed ID: 22591669
[TBL] [Abstract][Full Text] [Related]
2. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention.
Shah R; Jovin IS; Chaudhry A; Haji SA; Askari R; Dennis MM; Berzingi C; Rao SV
Catheter Cardiovasc Interv; 2019 Feb; 93(2):241-247. PubMed ID: 30269393
[TBL] [Abstract][Full Text] [Related]
4. Comparison of anti-thrombotic strategies using Bivalirudin, Heparin plus Glycoprotein IIb/IIIa inhibitors and Unfractionated Heparin Monotherapy for patients undergoing percutaneous coronary intervention - A single centre observational study.
Kaul U; Dua A; Sethi AK; Arambam P; Seth A
Indian Heart J; 2015; 67(4):311-7. PubMed ID: 26304562
[TBL] [Abstract][Full Text] [Related]
5. Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.
Bangalore S; Cohen DJ; Kleiman NS; Regev-Beinart T; Rao SV; Pencina MJ; Mauri L;
Circ Cardiovasc Interv; 2011 Oct; 4(5):463-73. PubMed ID: 21972401
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Safety and Efficacy of Unfractionated Heparin Versus Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention.
Rehmani A; Judkins C; Whelan A; Nguyen M; Schultz C
Heart Lung Circ; 2017 Dec; 26(12):1277-1281. PubMed ID: 28377232
[TBL] [Abstract][Full Text] [Related]
8. Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States.
Secemsky EA; Kirtane A; Bangalore S; Jovin IS; Patel D; Ferro EG; Wimmer NJ; Roe M; Dai D; Mauri L; Yeh RW
Circ Cardiovasc Qual Outcomes; 2017 Sep; 10(9):. PubMed ID: 28855222
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
[TBL] [Abstract][Full Text] [Related]
10. Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials.
Lee MS; Liao H; Yang T; Dhoot J; Tobis J; Fonarow G; Mahmud E
Int J Cardiol; 2011 Nov; 152(3):369-74. PubMed ID: 20843568
[TBL] [Abstract][Full Text] [Related]
11. Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial).
Parodi G; Migliorini A; Valenti R; Bellandi B; Signorini U; Moschi G; Buonamici P; Cerisano G; Antoniucci D
Am J Cardiol; 2010 Apr; 105(8):1053-9. PubMed ID: 20381652
[TBL] [Abstract][Full Text] [Related]
12. Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials.
Tarantini G; Brener SJ; Barioli A; Gratta A; Parodi G; Rossini R; Navarese EP; Niccoli G; Frigo AC; Musumeci G; Iliceto S; Stone GW
Am Heart J; 2014 Mar; 167(3):401-412.e6. PubMed ID: 24576526
[TBL] [Abstract][Full Text] [Related]
13. Effect of post-primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: A comprehensive pairwise and network meta-analysis of randomized controlled trials.
Shah R; Matin K; Rogers KC; Rao SV
Catheter Cardiovasc Interv; 2017 Aug; 90(2):196-204. PubMed ID: 27862911
[TBL] [Abstract][Full Text] [Related]
14. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.
Zhang Y; Zhang Y; Liu Z; Zhang B; Liu G; Chen K
Biomed Pharmacother; 2020 Oct; 130():110758. PubMed ID: 34321166
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
Auffret V; Leurent G; Boulmier D; Bedossa M; Zabalawi A; Hacot JP; Coudert I; Filippi E; Castellant P; Rialan A; Rouault G; Druelles P; Boulanger B; Treuil J; Avez B; Le Guellec M; Gilard M; Le Breton H
Arch Cardiovasc Dis; 2016 Dec; 109(12):696-707. PubMed ID: 27818120
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.
Cortese B; Micheli A; Picchi A; Bandinelli L; Brizi MG; Severi S; Limbruno U
Coron Artery Dis; 2009 Aug; 20(5):348-53. PubMed ID: 19543084
[TBL] [Abstract][Full Text] [Related]
17. Meta-Analysis of Effects of Bivalirudin Versus Heparin on Myocardial Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention.
Barria Perez AE; Rao SV; Jolly SJ; Pancholy SB; Plourde G; Rimac G; Poirier Y; Costerousse O; Bertrand OF
Am J Cardiol; 2016 Apr; 117(8):1256-66. PubMed ID: 26899489
[TBL] [Abstract][Full Text] [Related]
18. Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials.
Nairooz R; Sardar P; Amin H; Chatterjee S; Helmy T; Naidu SS
Catheter Cardiovasc Interv; 2015 Sep; 86(3):364-75. PubMed ID: 25914388
[TBL] [Abstract][Full Text] [Related]
19. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).
Stone GW; Clayton T; Deliargyris EN; Prats J; Mehran R; Pocock SJ
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):15-20. PubMed ID: 24140664
[TBL] [Abstract][Full Text] [Related]
20. The impact of unfractionated heparin or bivalirudin on patients with stable coronary artery disease undergoing percutaneous coronary intervention.
Lima FV; Gruberg L; Aslam U; Ramgadoo M; Clase K; Trevisan A; Jeremias A
J Interv Cardiol; 2018 Apr; 31(2):177-184. PubMed ID: 29205487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
